Cargando…

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status

SIMPLE SUMMARY: This retrospective observational study aims at highlighting the response to pertuzumab, trastuzumab and docetaxel treatment (THP), without using anthracycline, in patients with HER2-positive early breast cancer. We add evidence to the suitability of THP in real life to reach higher p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Irelli, Azzurra, Parisi, Alessandro, D’Orazio, Carla, Sidoni, Tina, Rotondaro, Silvia, Patruno, Leonardo, Pavese, Francesco, Bafile, Alberto, Resta, Valter, Pizzorno, Laura, Ciuffetelli, Virginia, Dal Mas, Antonella, Calvisi, Giuseppe, Di Sibio, Alessandra, Marzullo, Anna, Zelli, Veronica, Compagnoni, Chiara, Tessitore, Alessandra, Alesse, Edoardo, Ficorella, Corrado, Cortellini, Alessio, Cannita, Katia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220864/ https://www.ncbi.nlm.nih.gov/pubmed/35740668 http://dx.doi.org/10.3390/cancers14123003

Ejemplares similares

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis
por: Cocciolone, Valentina, et al.
Publicado: (2017)

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations
por: Cocciolone, Valentina, et al.
Publicado: (2018)

Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes
por: Zelli, Veronica, et al.
Publicado: (2020)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy
por: Irelli, Azzurra, et al.
Publicado: (2023)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting
por: Cannita, Katia, et al.
Publicado: (2016)

Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer
por: Zelli, Veronica, et al.
Publicado: (2020)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
por: Cortellini, Alessio, et al.
Publicado: (2018)

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2018)

Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma
por: Zelli, Veronica, et al.
Publicado: (2022)

Emerging Role of isomiRs in Cancer: State of the Art and Recent Advances
por: Zelli, Veronica, et al.
Publicado: (2021)

Classification of tumor types using XGBoost machine learning model: a vector space transformation of genomic alterations
por: Zelli, Veronica, et al.
Publicado: (2023)

MiR-182-5p Is Upregulated in Hepatic Tissues from a Diet-Induced NAFLD/NASH/HCC C57BL/6J Mouse Model and Modulates Cyld and Foxo1 Expression
por: Compagnoni, Chiara, et al.
Publicado: (2023)

MicroRNAs Expression in Response to rhNGF in Epithelial Corneal Cells: Focus on Neurotrophin Signaling Pathway
por: Compagnoni, Chiara, et al.
Publicado: (2022)

Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells
por: Clementi, Letizia, et al.
Publicado: (2023)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
por: Parisi, Alessandro, et al.
Publicado: (2019)

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
por: Napoleoni, Luca, et al.
Publicado: (2019)

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
por: Irelli, A., et al.
Publicado: (2014)

Next-generation sequencing: recent applications to the analysis of colorectal cancer
por: Del Vecchio, Filippo, et al.
Publicado: (2017)

Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy
por: Cortellini, Alessio, et al.
Publicado: (2017)

Allostatic Load as an Insight into the Psychological Burden after Primary Treatment in Women with Breast Cancer: Influence of Physical Side Effects and Pain Perception
por: Irelli, Azzurra, et al.
Publicado: (2022)

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study
por: Krop, Ian E., et al.
Publicado: (2022)

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
por: Gamucci, Teresa, et al.
Publicado: (2018)

Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
por: Zhang, Jing, et al.
Publicado: (2017)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
por: Bruera, Gemma, et al.
Publicado: (2013)

Single‐institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non‐small cell lung cancer patients treated with first‐line chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2018)

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

Pertuzumab in Metastatic Breast Cancer
por: Patel, Rachana, et al.
Publicado: (2012)

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report
por: Cortellini, Alessio, et al.
Publicado: (2019)

Ultrasound-Based Method for the Identification of Novel MicroRNA Biomarkers in Prostate Cancer
por: Cornice, Jessica, et al.
Publicado: (2021)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A “snapshot” from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2017)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
por: Perez, Edith A., et al.
Publicado: (2019)

Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017)

Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors
por: Tessitore, Alessandra, et al.
Publicado: (2013)

The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages
por: Capece, Daria, et al.
Publicado: (2013)

Rare bone toxicity associated with vismodegib
por: Ciciarelli, Valeria, et al.
Publicado: (2020)

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
por: Perez, Edith A., et al.
Publicado: (2019)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
por: Hughes, Juliana Bentes, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_i0se69u4853m5mqfg4hm7rm51h